IDEXX Laboratories (IDXX) Receives Sell Rating from Aegis

Aegis restated their sell rating on shares of IDEXX Laboratories (NASDAQ:IDXX) in a research note released on Friday.

Other equities research analysts have also issued reports about the company. Canaccord Genuity reissued a buy rating and set a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Bank of America raised IDEXX Laboratories from a neutral rating to a buy rating and set a $175.00 price target for the company in a research note on Wednesday, August 23rd. Stifel Nicolaus restated a buy rating and set a $185.00 price objective on shares of IDEXX Laboratories in a report on Monday, August 21st. Finally, Zacks Investment Research upgraded IDEXX Laboratories from a hold rating to a buy rating and set a $184.00 price objective on the stock in a report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $173.67.

Shares of IDEXX Laboratories (NASDAQ IDXX) opened at $159.70 on Friday. IDEXX Laboratories has a one year low of $113.92 and a one year high of $173.01. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48. The stock has a market capitalization of $14,004.71, a P/E ratio of 54.06, a P/E/G ratio of 2.43 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same period last year, the company earned $0.62 EPS. IDEXX Laboratories’s quarterly revenue was up 9.7% compared to the same quarter last year. analysts anticipate that IDEXX Laboratories will post 3.24 earnings per share for the current fiscal year.

In other IDEXX Laboratories news, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total transaction of $312,140.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $148.35, for a total value of $2,670,300.00. Following the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at $157,929,404.55. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock worth $16,686,200 over the last 90 days. 2.77% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of IDEXX Laboratories by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock valued at $1,495,488,000 after acquiring an additional 354,024 shares during the period. BlackRock Inc. increased its holdings in shares of IDEXX Laboratories by 10.5% in the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares during the period. Koch Industries Inc. increased its holdings in shares of IDEXX Laboratories by 44,533.1% in the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares during the period. Renaissance Technologies LLC increased its holdings in shares of IDEXX Laboratories by 38.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after acquiring an additional 376,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of IDEXX Laboratories by 42.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares during the period. Institutional investors own 86.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://weekherald.com/2017/12/12/idexx-laboratories-idxx-receives-sell-rating-from-aegis.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply